PDUFAs produce yawns
Buysiders see HCV big again in 2012, along with cancer, autoimmune therapies
There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders. Investors are focusing on areas such as HCV, which is almost unanimously seen as maintaining its momentum into 2012, while oral autoimmune therapies and selected cancer products are also attracting attention.
According to buysiders, the large number of compounds under review at FDAdoes not equate to a large amount of excitement. Kurt von Emster of venBio described the PDUFA dates for 2012 as having "marginal impact." OrbiMed's Sven Borho echoed this, saying it is "not the greatest year" for approvals.
A few potential approvals are attracting attention. Eric Roberts of Caxton Advantage and Deka Investment's Kai Bruening like the chances of ridaforolimus from Ariad Pharmaceuticals Inc. and partner Merck & Co. Inc. to treat metastatic soft tissue or bone sarcomas. The compound has a June 5 PDUFA date.
Buysiders Joep Muijrers of LSP and International Biotechnology Trust's David Pinniger also like Ironwood Pharmaceuticals Inc.'s linaclotide, which is under review to treat chronic constipation and irritable bowel syndrome with constipation (IBS-C). The PDUFA date is expected in June. Ironwood will co-commercialize linaclotide in the U.S. with Forest Laboratories Inc.
Roberts also named Ironwood as fitting the profile of a potential takeout target - having a Phase III or marketed product while retaining a significant part of the economics of the asset. However, such a deal won't be straightforward, as the company created two classes of shares in its 2010 IPO (see BioCentury, Feb. 1, 2010).
Amarin Corp. plc is another mid-cap with an upcoming FDA action that Muijrers and Roberts tip as a potential takeout target, given the good Phase III data for its AMR101 in hypertriglyceridemia. The compound has a July 26 PDUFA date (see BioCentury, Dec. 6, 2010).
HCV big again
Buysiders expect HCV to continue to be the hot area in 2012, following the 2011 launches of protease inhibitors Incivek telaprevir from Vertex Pharmaceuticals Inc. and Victrelis boceprevir from Merck, as well as Gilead Sciences Inc.'s proposed acquisition of Pharmasset Inc. for about $11 billion.
This year could see the fast rise of second-generation products. In particular, Harald Schwarz of Medical Strategy named TMC435, a once-daily protease inhibitor from Medivir AB and Johnson & Johnson. "Most participants in the market expect that if the second-generation products are approved, Incivek will lose market share at once," he said.
Data are expected this year from three Phase III trials of TMC435 in HCV genotype 1.
Investors also are looking for data in 2012 to elucidate whether protease inhibitors will remain a key component in oral HCV cocktails. These include Phase II trials of TMC435 plus Pharmasset's PSI-7977; Vertex's VX-222, a non-nucleoside HCV NS5B polymerase inhibitor plus Incivek; and Bristol-Myers Squibb Co.'s daclatasvir, an HCV NS5A protein inhibitor, plus PSI-7977.
Beyond the data, investors are expecting further consolidation in the space. Almost all cited three HCV plays as likely to enter partnerships or be acquired in 2012: Idenix Pharmaceuticals Inc., Achillion Pharmaceuticals Inc. and Inhibitex Inc.
As BB Biotech's Daniel Koller noted: "I think in HCV we are far from over. It's still more a question of will it be partnerships or straightforward acquisitions."
Late on Saturday, Inhibitex announced it has opted for the latter, having reached a definitive agreement to be acquired by Bristol-Myers for $26 per share in cash, or $2.5 billion. Shareholders owning 17% of the biotech have already agreed to tender their shares.
Inhibitex's lead program is nucleotide polymerase inhibitor INX-189, which is in Phase II testing. The other two HCV picks have multiple unpartnered HCV assets, with Idenix being the most advanced. Its nucleotide polymerase inhibitor IDX184 is in Phase IIb testing. Achillion's lead is ACH-1625, an HCV NS3 protease inhibitor in Phase II (see BioCentury, Oct. 31, 2011).
Before the Inhibitex announcement, Pinniger said his money was on Achillion to be the next HCV takeout.
Autoimmune goes oral
Investors are also eyeing the oral autoimmune space for 2012, in particular oral therapies in multiple sclerosis (MS) and Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA).
Roberts said "autoimmune is certainly the biggest story for 2012."
With impressive data last year, Pinniger said Biogen Idec Inc.'s BG-12 is already "transitioning to a commercial positioning story, and I think everyone is now beginning to have to think about the implications of success for BG-12 on the rest of Biogen's business."
Biogen plans to submit an NDA for BG-12 in 1H12.
Muijrers will be looking at whether Novartis AG's Gilenya fingolimod can pick up market share before BG-12 enters the market. The sphingosine 1-phosphate (S1P) receptor agonist had 3Q11 sales of $153 million, up from $4 million in 3Q10. The drug was approved in the U.S. and Russia in September 2010.
In RA, buysiders such as Schwarz, Muijrers and Miller Tabak's Les Funtleyder said they are looking at how quickly the market will accept oral JAK inhibitors. Pfizer Inc.'s tofacitinib is leading the way with a PDUFA date in August. It is also under review in the EU.
Finally, Koller is also looking forward to data for apremilast, Celgene Corp.'s oral phosphodiesterase-4 (PDE-4) inhibitor. The company expects to have Phase III results in psoriasis and psoriatic arthritis in mid-2012 and Phase IIb data in RA in 1H12.